843P Challenges and insights in treating Langerhans cell histiocytosis: Persistent mutations and novel therapeutic approaches von Nashvi, M., Hélias-Rodzewicz, Z., Rengassamy, J., Bigenwald, C., Quivoron, C., Emile, J-F., Urvoy, N., Haroche, J., Héritier, S.

Volltext

586P BRCA1, BRCA2 and RAD51C somatic RNAseq study in ovarian cancer: A description of physiological and pathogenic splicing patterns von Sebai, M., Tang, R., Le Formal, A., Nashvi, M., Leary, A., Rouleau, E.

Volltext

587P Sequential approach to determine the HRD status with BRCA1 promotor methylation status and shallow whole genome sequencing (sWGS) von Rouleau, E., Blanc-Durand, F., Nashvi, M., Cotteret, S., Genestie, C., Le Formal, A., Pommier, M., Vasseur, D., Adnani, Y., Lacroix, L., Leary, A., Tang, R.

Volltext

584P Mutation analysis of ovarian carcinoma patients presenting optimal response to neoadjuvant chemotherapy von Dos Santos, E.S., Yaniz Galende, E., Caputo, S.M., da Costa, A.A.B.A., Nashvi, M., Maella, F., Lacroix, L., Auguste, A., Le Formal, A., De Brot Andrade, L., Miranda, V.C., P.E. Diz, M.D., Vasconcelos, M., Pautier, P., Morice, P., Genestie, C., Leary, A., Rouleau, E.

Volltext